- Home
- GXO vs NUVL Comparison
GXO vs NUVL Comparison
Compare GXO & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXO
- NUVL
- Stock Information
- Founded
- GXO 2021
- NUVL 2017
- Country
- GXO United States
- NUVL United States
- Employees
- GXO N/A
- NUVL N/A
- Industry
- GXO Transportation Services
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- GXO Consumer Discretionary
- NUVL Health Care
- Exchange
- GXO Nasdaq
- NUVL Nasdaq
- Market Cap
- GXO 4.8B
- NUVL 5.4B
- IPO Year
- GXO N/A
- NUVL 2021
- Fundamental
- Price
- GXO $50.35
- NUVL $80.54
- Analyst Decision
- GXO Buy
- NUVL Strong Buy
- Analyst Count
- GXO 13
- NUVL 10
- Target Price
- GXO $55.54
- NUVL $119.60
- AVG Volume (30 Days)
- GXO 1.6M
- NUVL 562.5K
- Earning Date
- GXO 08-05-2025
- NUVL 08-07-2025
- Dividend Yield
- GXO N/A
- NUVL N/A
- EPS Growth
- GXO N/A
- NUVL N/A
- EPS
- GXO 0.62
- NUVL N/A
- Revenue
- GXO $12,230,000,000.00
- NUVL N/A
- Revenue This Year
- GXO $9.65
- NUVL N/A
- Revenue Next Year
- GXO $5.97
- NUVL N/A
- P/E Ratio
- GXO $80.55
- NUVL N/A
- Revenue Growth
- GXO 23.40
- NUVL N/A
- 52 Week Low
- GXO $30.46
- NUVL $55.54
- 52 Week High
- GXO $63.33
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- GXO 74.23
- NUVL 59.85
- Support Level
- GXO $48.34
- NUVL $76.27
- Resistance Level
- GXO $49.96
- NUVL $80.90
- Average True Range (ATR)
- GXO 1.36
- NUVL 2.55
- MACD
- GXO 0.33
- NUVL 0.19
- Stochastic Oscillator
- GXO 96.21
- NUVL 81.61
About GXO GXO Logistics Inc.
GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.